Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 12/20 | 0.66 |
| ▸ | JAK2 | O60674 | 12/20 | 0.64 |
| ▸ | TYK2 | P29597 | 3/20 | 0.53 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302399 | 1.00 | JAK1 (0.66) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL3304434 | 0.91 | JAK1 (0.69) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL3300304 | 0.83 | JAK1 (0.59) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL11916701 | 0.80 | JAK1 (1.00) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL2144198 | 0.79 | JAK1 (0.46) | JAK1JAK2TYK2JAK3SYK | |
| SCHEMBL2144191 | 0.79 | JAK1 (0.46) | JAK1JAK2TYK2JAK3SYK | |
| SCHEMBL2237531 | 0.78 | JAK2 (1.00) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL31429929 | 0.75 | JAK2 (0.56) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL2242877 | 0.74 | JAK2 (1.00) | JAK1JAK2TYK2JAK3IKBKB | |
| SCHEMBL30411111 | 0.74 | JAK1 (0.47) | JAK1JAK2TYK2JAK3IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK1 69/4885JAK2 26/4885TYK2 21/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | JAK1 69/4885JAK2 26/4885TYK2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.